Urothelial carcinoma of the bladder: definition, treatment and future efforts.
about
Normal and neoplastic urothelial stem cells: getting to the root of the problemProtein Profiling of Bladder Urothelial Cell CarcinomaGenetic and Epigenetic Alterations in Bladder CancerMicroRNAs as biomarkers associated with bladder cancer.Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study (MOVIE-GOIRC 01-2014).Knockdown of regulator of cullins-1 (ROC1) expression induces bladder cancer cell cycle arrest at the G2 phase and senescence.Lack of decorin expression by human bladder cancer cells offers new tools in the therapy of urothelial malignanciesUpregulated WDR5 promotes proliferation, self-renewal and chemoresistance in bladder cancer via mediating H3K4 trimethylation.Modelling bladder cancer in mice: opportunities and challenges.MicroRNA-320c inhibits tumorous behaviors of bladder cancer by targeting Cyclin-dependent kinase 6Efficacy and safety of Vinflunine for advanced or metastatic urothelial carcinoma in routine practice based on the French multi-centre CURVE study.CLASP2 is involved in the EMT and early progression after transurethral resection of the bladder tumor.The prognostic significance of DAPK1 in bladder cancer.CMTM8 inhibits the carcinogenesis and progression of bladder cancerMethylomics analysis identifies ZNF671 as an epigenetically repressed novel tumor suppressor and a potential non-invasive biomarker for the detection of urothelial carcinoma.Overexpression of RNF2 Is an Independent Predictor of Outcome in Patients with Urothelial Carcinoma of the Bladder Undergoing Radical Cystectomy.ATR-Chk1 signaling inhibition as a therapeutic strategy to enhance cisplatin chemosensitivity in urothelial bladder cancer.TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphismMetformin represses bladder cancer progression by inhibiting stem cell repopulation via COX2/PGE2/STAT3 axis.Alterations of DNA methylome in human bladder cancer.Cantharidin alters the expression of genes associated with the NKG2D-associated immune response in TSGH-8301 human bladder carcinoma cells.Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2.ARF Confers a Context-Dependent Response to Chemotherapy in Muscle-Invasive Bladder CancerQuantitative proteomics of fractionated membrane and lumen exosome proteins from isogenic metastatic and nonmetastatic bladder cancer cells reveal differential expression of EMT factors.Urothelial generation and regeneration in development, injury, and cancer.Do histological variants in urothelial carcinoma of the bladder portend poor prognosis? A systematic review and meta-analysisCyclin-dependent kinase 4 is a novel target in micoRNA-195-mediated cell cycle arrest in bladder cancer cells.Insights from animal models of bladder cancer: recent advances, challenges, and opportunities.Overexpression of HMGB3 protein promotes cell proliferation, migration and is associated with poor prognosis in urinary bladder cancer patients.Proteomics analysis of bladder cancer invasion: Targeting EIF3D for therapeutic intervention.Bladder cancers arise from distinct urothelial sub-populations.Uncovering the clinical utility of miR-143, miR-145 and miR-224 for predicting the survival of bladder cancer patients following treatment.PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors.Inflammatory microenvironment in the initiation and progression of bladder cancer.Expression of ganglioside GD2, reprogram the lipid metabolism and EMT phenotype in bladder cancer.The Stromal Niche for Epithelial Stem Cells: A Template for Regeneration and a Brake on Malignancy.Clinical Proteomics for Precision Medicine: The Bladder Cancer Case.Prognostic Power of a Tumor Differentiation Gene Signature for Bladder Urothelial Carcinomas.miR-221/222 cluster expression improves clinical stratification of non-muscle invasive bladder cancer (TaT1) patients' risk for short-term relapse and progression.Significant expression of CHK1 and p53 in bladder urothelial carcinoma as potential therapeutic targets and prognosis.
P2860
Q26825948-E761E59E-C741-4E19-AEFF-C8EE0DDAA844Q27324419-C8AB0B88-06F3-435C-A9A8-258CAC673C78Q28074732-8E077551-383A-4A2C-A45C-EF1E227A53CBQ33642335-9BC63B69-5532-4661-AD8D-2BAA752F54F6Q33919252-F2452680-6ECC-4148-AF3C-9F885EDBE44CQ34717627-388D79A6-CC92-496C-BE41-9A538D3D463EQ35022673-41E987E0-9E32-4590-8697-A2E8C6E96CB3Q35056092-65DCF5EB-898F-48D0-B67A-34D478C9EDC3Q35285703-D5DAE277-E0B3-4EBC-8B22-6520B73C1E6AQ35605883-BA4CB668-32F8-4648-99B7-83681A6BC2B8Q35956711-B19E0FF2-DB45-48D2-9658-77082C1F1372Q36272100-70E3993A-51E2-408F-92AF-EC8C70A6C0EDQ36339910-CFC7893A-C477-47E0-AD89-49061B83D528Q36490303-69231F6C-D01B-40CB-840B-4E02DFAD3BD9Q36557362-3DCA753E-0D08-4A4F-B577-92FA028B827DQ36574137-FC9278D5-3645-4BA4-BA7E-FAF58747E4C5Q36739002-727A3794-9B65-4C2C-8475-2CEE8252749FQ37256055-AF286732-96B5-43ED-BBD5-22DDD825F750Q37317523-514D3C7A-D103-40A6-A732-DB127B3F8092Q38131409-6EE90745-2471-4477-86CE-06E0397F0A5DQ38686052-B81D049F-8B2F-4C3A-8804-833DB49BDC32Q38715315-9465222D-689F-4AB0-B225-BCE2696749B7Q38721568-B2C3AA1F-9065-4754-9AB2-0AB86000694BQ39038597-DCC8589E-340F-4BC1-B2A0-0D01C14F4229Q39097235-544CE797-38A4-41F3-96A8-18E4977D51F1Q39318239-B7EB5BF9-0808-48C2-AD2E-244BD4FF69E6Q39404314-CA632B8E-5FCF-44B8-9A72-18CC4B852AEAQ41339763-B86B1803-4EDA-4FEF-868F-84801D118C63Q41486372-E738601E-21EA-4C80-965D-7D10F70996CDQ42378347-3839BCEF-8443-465C-B35F-7CA8755B97B5Q42465565-BBB7E302-F985-456A-8017-FE6FB8CEEF6CQ43717784-50B11AAF-1842-45F9-B35C-B6A80B5AFB66Q44581657-B7A74098-08DB-44B2-8AC4-E095047B862FQ46779353-2D23A7B1-B1E9-4DCF-AA65-2E4CA6D97F01Q47170529-7C03A535-1E4A-48D4-8C87-38E2DA316650Q47670544-E3DFAD9E-B5DB-43E3-A6B2-D6538582FB77Q47694209-BC5A2CB9-1A55-42F4-B6BA-86B66E70824AQ47727562-92CD50BB-4AE9-401D-AF22-D7D92FB3C831Q48225163-5E1C784B-47B4-4475-B167-A73903683BC7Q49168184-1002040A-7067-4A94-B06B-E3A6FF92AC42
P2860
Urothelial carcinoma of the bladder: definition, treatment and future efforts.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Urothelial carcinoma of the bladder: definition, treatment and future efforts.
@en
Urothelial carcinoma of the bladder: definition, treatment and future efforts.
@nl
type
label
Urothelial carcinoma of the bladder: definition, treatment and future efforts.
@en
Urothelial carcinoma of the bladder: definition, treatment and future efforts.
@nl
prefLabel
Urothelial carcinoma of the bladder: definition, treatment and future efforts.
@en
Urothelial carcinoma of the bladder: definition, treatment and future efforts.
@nl
P2093
P2860
P356
P1476
Urothelial carcinoma of the bladder: definition, treatment and future efforts.
@en
P2093
G Joel Decastro
Gary D Steinberg
Sandip M Prasad
P2860
P2888
P304
P356
10.1038/NRUROL.2011.144
P407
P577
2011-10-11T00:00:00Z